目的：分析重组牛碱性成纤维细胞生长因子(rb-bFGF)滴眼液联合氟米龙滴眼液治疗重度干眼合并角膜损伤的临床效果。

方法：回顾性分析，收集2022年1月至2024年12月医院收治白内障超声乳化术后并发重度干眼伴角膜损伤的患者资料。根据干眼治疗方案不同分为两组：对照组给予常规人工泪液+氟米龙滴眼液治疗； 观察组给予常规人工泪液+rb-bFGF滴眼液联合氟米龙滴眼液治疗，总疗程均为8 wk。比较两组治疗前，治疗后4、8 wk眼表疾病指数(OSDI)评分、泪膜破裂时间(BUT)、角膜荧光素钠染色(FL)评分、泪液炎性因子\〖白细胞介素-1β(IL-1β)和白细胞介素-18(IL-18)\〗。统计治疗期间两组眼部不良反应发生情况。

结果：本研究共纳入患者104例104眼，对照组50例50眼(年龄61.38±4.35岁，男28例，女22例)，观察组54例54眼(年龄60.75±4.52岁，男27例，女27例)。治疗后4、8 wk，两组OSDI评分、FL评分、泪液中IL-1β、IL-18均低于治疗前，BUT均高于治疗前(均P<0.05)，观察组OSDI评分、FL评分、泪液中IL-1β、IL-18均低于对照组，BUT均高于对照组(均P<0.001)。治疗随访期间两组眼部不良反应发生率比较无差异(P>0.05)。

结论：rb-bFGF滴眼液联合氟米龙滴眼液治疗可有效改善重度干眼合并角膜损伤患者干眼症状，有助于泪膜稳定性提高及角膜损伤修复，且可抑制眼表炎症，安全性尚可。

METHODS: A retrospective analysis was conducted on patients with severe dry eye syndrome and corneal injury after cataract phacoemulsification surgery admitted to the hospital from January 2022 to December 2024. According to different treatment plans for dry eye syndrome, patients were divided into two groups: a control group was treated with conventional artificial tears and fluorometholone eye drops for a course of 8 wk; an observation group were treated with conventional artificial tears+rb-bFGF eye drops combined with fluorometholone eye drops for a course of 8 wk. The ocular surface disease index(OSDI), tear film breakup time(BUT), corneal fluorescein staining(FL)score, and tear inflammatory factors \〖interleukin-1 β(IL-1β)and interleukin-18(IL-18)\〗 were compared between the two groups before and 4 and 8 wk after treatment. The occurrence of adverse reactions in the eyes of two groups during the treatment period was statistically analyzed.

RESULTS:This study included a total of 104 patients(104 eyes), with a control group of 50 patients(age 61.38±4.35 y, 28 males and 22 females)and an observation group of 54 patients(age 60.75±4.52 y, 27 males and 27 females). After 4 and 8 wk of treatment, the OSDI, FL, and IL-1 β and IL-18 in tears of both groups were lower than before treatment, and the BUT was higher than before treatment(all P<0.05). The OSDI, FL, and IL-1β and IL-18 in tears of the observation group were lower than those of the control group, and the BUT was higher than that of the control group(all P<0.001). During the follow-up period of treatment, there was no statistical significant difference in the incidence of eye adverse reactions between the two groups of patients(P>0.05).

CONCLUSION: The combination of rb-bFGF eye drops and fluorometholone eye drops can effectively improve dry eye symptoms in patients with severe dry eye syndrome and corneal injury, promote tear film stability and corneal injury repair, inhibit ocular surface inflammation, and has acceptable safety.